GE Healthcare to Invest $1B in Cancer R&D Including Biomarker Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GE Healthcare today announced plans to dedicate $1 billion in research and development spending over the next five years to expand its cancer diagnostic and molecular imaging capabilities, technologies for manufacturing biopharmaceuticals, and cancer research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.